GLP-1 Safety Knowledge: Student Survey

A cross-sectional survey at Umm Al-Qura University in Saudi Arabia found limited knowledge of GLP-1 receptor agonist adverse effects among pharmacy students. Of 1,118 eligible students, 296 responded, and their mean knowledge score was 7.6 out of 17^[1]. The paper did not test a medicine, measure patient outcomes, or compare treatments. It measured what one student group knew and believed during November and December 2025. That design boundary matters when reading the percentages.

The survey measured knowledge, not care

The researchers invited undergraduate Doctor of Pharmacy students from years one through seven. They used a newly developed questionnaire with 17 knowledge items and five attitude items covering indications, mechanisms, adverse effects, and clinical scenarios. Two experts reviewed the questionnaire, and 10 students took part in pilot testing^[2]. Those steps describe early content review and testing. The abstract does not report a previously established external benchmark for the score, so 7.6 out of 17 should be read as the result on this questionnaire rather than a universal cutoff for adequate knowledge.

The sample was 63.9% male. The 296 completed responses produced a 26.5% response rate, which leaves substantial room for nonresponse bias. Students who chose to answer may have differed from those who did not. The study also came from one university, so it cannot establish what pharmacy students across Saudi Arabia or other countries know. Cross-sectional data capture one period and cannot show whether coursework caused a score or whether knowledge later changed.^[2]

Recognition varied by adverse effect

Nausea was the most frequently recognized adverse effect, identified by 59.1% of respondents. Recognition was lower for thyroid C-cell tumors observed in rodent studies, at 25.0%, and diabetic retinopathy complications, at 36.5%. Only 37.2% correctly identified that hypoglycemia is uncommon with GLP-1 receptor agonist monotherapy^[1]. These percentages describe answers to survey items. They are not estimates of how often those events occur in patients.

The paper concerns the drug class rather than a head-to-head evaluation of individual products. Its indexed keywords include semaglutide, but the reported abstract does not provide product-specific knowledge scores. Readers looking for medicine-specific evidence should use the semaglutide safety summary and check the current prescribing information in their jurisdiction. A class-level survey cannot determine the risk profile of one product or tell a patient which treatment fits them.

Students wanted more safety education

Most respondents agreed that adverse effects significantly affect clinical use, at 59.4%. A similar share, 61.1%, supported further education about less common side effects^[2]. The authors described attitudes as generally positive despite limited knowledge. That conclusion reflects willingness to learn and acknowledgment of safety concerns. It does not show counseling competence in a pharmacy, accurate decisions with real patients, or improved outcomes after an educational program.

Regression analyses found that higher knowledge scores were associated with greater self-reported confidence in knowledge. The reported odds ratio was 1.11 for each score unit, with a 95% confidence interval from 1.06 to 1.17. Higher scores were also associated with stronger support for more education on less common adverse effects, with an odds ratio of 1.11 and a 95% confidence interval from 1.06 to 1.18. Both associations had p values below 0.001^[1]. Gender and academic year did not significantly predict any attitude item in the reported models.

An odds ratio here describes an association between survey responses after adjustment in the authors' model. It does not mean that raising a knowledge score by one point will cause an 11% increase in confidence or support for education. Knowledge and confidence were recorded at the same time, and either may track other unmeasured differences. The abstract does not expose every modeling choice or the full questionnaire, which limits independent interpretation.

What the study can support

The study supports a focused curriculum signal. In this participating group, fewer than four in 10 respondents correctly recognized the monotherapy hypoglycemia point, and recognition differed across named safety topics. The authors argue for stronger pharmacovigilance and evidence-based medication-safety teaching within pharmacy curricula^[2]. A sensible next research step would test a defined educational intervention with a validated assessment and follow students over time. It could also measure application to counseling scenarios rather than relying only on recognition items.

The findings do not support conclusions about the safety of semaglutide or any other GLP-1 medicine. They also do not show that surveyed students gave unsafe advice to patients. No patients participated, no prescriptions were reviewed, and no adverse events were counted. The study's value lies in identifying possible educational gaps that deserve direct testing, not in grading a profession from one voluntary survey.

What we do not yet know

The abstract does not report how knowledge differed across individual academic years, whether respondents had completed relevant pharmacology teaching, or how the new questionnaire performed beyond expert review and a 10-student pilot. It does not show whether the same items would produce similar scores at another institution. The low response rate also prevents a confident estimate for all eligible students. Full reporting of item wording, missing-data handling, reliability, and score distribution would help readers judge the instrument and the result.

For patients, the practical message is narrower. A survey of pharmacy students cannot replace advice from a qualified healthcare professional who knows the exact medicine, other treatments, and medical history. It does show why medication-safety education needs to distinguish common adverse effects from rare warnings and explain when risks depend on combination therapy. Those lessons should be evaluated in practice before anyone claims that a curriculum change improves counseling or patient safety.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.